Authorized purpose: The ACUSON systems are intended to provide images or signals from inside the body by appropriately trained healthcare professionals in clinical settings for fetal, abdominal, pediatric, neonatal cephalic, small-parts, OB/GYN, cardiac, transesophageal, pelvic, vascular, adult-cephalic, musculoskeletal, and peripheral-vascular applications.
Clinical role
Diagnostic ultrasound acquisition, fluid or signal analysis, measurement, and image review under professional control.
Keep in mind: The FDA submission is a release-specific device record; exact model, transducer, application, software option, patient, and measurement-package applicability must be confirmed before use.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: The ACUSON systems are intended to provide images or signals from inside the body by appropriately trained healthcare professionals in clinical settings for fetal, abdominal, pediatric, neonatal cephalic, small-parts, OB/GYN, cardiac, transesophageal, pelvic, vascular, adult-cephalic, musculoskeletal, and peripheral-vascular applications.
Which images or clinical context are in scope?Modality: Ultrasound Anatomy or clinical context: Fetal/obstetric, abdominal, pelvic, cardiac, vascular, cephalic, small-organ, musculoskeletal, and urologic anatomy Input: Ultrasound data acquired with the exact labeled system, transducers, patient, application, and operating mode.
Who uses it?Intended users: Appropriately trained healthcare professionals qualified for direct use of diagnostic ultrasound devices.
What does the software produce?Output: Ultrasound images, signals, measurements, calculations, and displayed or recorded results for professional review.
What is its most important limitation?Key limitation: The FDA submission is a release-specific device record; exact model, transducer, application, software option, patient, and measurement-package applicability must be confirmed before use.
Clinical takeaway. Clinical role: The ACUSON systems are intended to provide images or signals from inside the body by appropriately trained healthcare professionals in clinical settings for fetal, abdominal, pediatric, neonatal cephalic, small-parts, OB/GYN, cardiac, transesophageal, pelvic, vascular, adult-cephalic, musculoskeletal, and peripheral-vascular applications.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports nonclinical evaluation of acoustic output, biocompatibility, cleaning and disinfection, and thermal, electrical, electromagnetic and mechanical safety, plus performance testing for expanding UDFF to pediatrics in 105 patients aged 8 - 17 years from two institutions in the US and France, with MRI PDFF as the reference standard. UDFF showed an AUROC ≥ 0.87 against MRI-PDFF and a test-retest ICC ≥ 0.97. Results are as reported in the FDA submission, not independent validation.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
The ACUSON systems are intended to provide images or signals from inside the body by appropriately trained healthcare professionals in clinical settings for fetal, abdominal, pediatric, neonatal cephalic, small-parts, OB/GYN, cardiac, transesophageal, pelvic, vascular, adult-cephalic, musculoskeletal, and peripheral-vascular applications.
The FDA submission is a release-specific device record; exact model, transducer, application, software option, patient, and measurement-package applicability must be confirmed before use.
The exact FDA document reports nonclinical evaluation of acoustic output, biocompatibility, cleaning and disinfection, and thermal, electrical, electromagnetic and mechanical safety, plus performance testing for expanding UDFF to pediatrics in 105 patients aged 8 - 17 years from two institutions in the US and France, with MRI PDFF as the reference standard. UDFF showed an AUROC ≥ 0.87 against MRI-PDFF and a test-retest ICC ≥ 0.97. Results are as reported in the FDA submission, not independent validation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "The subject devices have been evaluated for acoustic output, biocompatibility, cleaning and disinfection effectiveness as well as thermal, electrical, electromagnetic and mechanical safety" … "The studies included a total of 105 patients, with 40 patients scanned with the DAX transducer, 27 patients with the 5C1 transducer, and 38 patients with the 9C2 transducer. - Data were collected from two institutions in the US and France.". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA document reports nonclinical evaluation of acoustic output, biocompatibility, cleaning and disinfection, and thermal, electrical, electromagnetic and mechanical safety, plus performance testing for expanding UDFF to pediatrics in 105 patients aged 8 - 17 years from two institutions in the US and France, with MRI PDFF as the reference standard. UDFF showed an AUROC ≥ 0.87 against MRI-PDFF and a test-retest ICC ≥ 0.97. Results are as reported in the FDA submission, not independent validation.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "The subject devices have been evaluated for acoustic output, biocompatibility, cleaning and disinfection effectiveness as well as thermal, electrical, electromagnetic and mechanical safety" … "The studies included a total of 105 patients, with 40 patients scanned with the DAX transducer, 27 patients with the 5C1 transducer, and 38 patients with the 9C2 transducer. - Data were collected from two institutions in the US and France.". Read from the exact FDA decision document on 2026-11-14.
Sensitivity is not a product-wide endpoint for this system or software function. Compare only an exact endpoint, threshold, population, version, and source if later verified.
Reported specificity
Not applicable
Not applicable
Not applicable
Checked 2026-09-04
Specificity is not a product-wide endpoint for this system or software function. Compare only an exact endpoint, threshold, population, version, and source if later verified.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K240704 FDA decision evidence for ACUSON Sequoia Diagnostic Ultrasound System, ACUSON Sequoia Select Diagnostic Ultrasound System, ACUSON Origin Diagnostic Ultrasound System, ACUSON Origin ICE Diagnostic Ultrasound System
DesignFDA 510(k) substantial-equivalence review of the exact submission, device description, indications, and verification or validation documentation.
Tested versionACUSON Sequoia, Sequoia Select, Origin, and Origin ICE Diagnostic Ultrasound Systems
IndependenceSponsor or vendor study
K240704
The FDA decision material is manufacturer-submitted regulatory evidence. It is not independent clinical validation, and local technical, clinical, privacy, security, and workflow acceptance remains necessary.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K240704 by exact native submission identifier. This does not exclude product-family, later, or adverse-event information.
Public source
Exact FDA submission
Checked 2026-09-04
Exact-identifier review does not prove absence of all product-family safety signals.
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, surgical, or diagnostic service line and verify payer, site-of-service, and coding assumptions independently.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Ultrasound data acquired with the exact labeled system, transducers, patient, application, and operating mode.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. The exact FDA decision material does not establish a complete integration contract. Confirm DICOM, worklist, identity, interfaces, exports, routing, audit behavior, archive, and downtime locally.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Field checked 2026-09-04 ·
AI processing
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. The exact FDA decision material does not establish the complete deployment topology, hosting responsibility, availability, upgrade path, or service contract.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-04 ·
Returned objects
Source context, not route validation: Ultrasound images, signals, measurements, calculations, and displayed or recorded results for professional review.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Ultrasound images, signals, measurements, calculations, and displayed or recorded results for professional review.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Siemens Healthineers' corporate cybersecurity page states a Secure Development Lifecycle addressing pre-market and post-market phases for products under development and a range of existing offerings; a Cybersecurity Management Service maintaining a product security inventory (over 1,000 product versions and over 21,000 monitored software components) with security whitepapers, SBOMs and vulnerability assessments available to customers via teamplay Fleet; incident and vulnerability management channels; and that Siemens Healthineers AG maintains an independent certification of its global Cybersecurity Management System to ISO/IEC 27001:2022 extended by ISO/IEC 27701:2019, with the certificate referenced to the SGS directory. Vendor statement; no certificate or report was read.
Vendor-wide
Checked 2026-10-26
Vendor statement, not an attestation. Identity bridge: Siemens Healthineers' own corporate-info page names Siemens Medical Solutions USA, Inc. (Malvern, PA), and its 2024 governance press release states Siemens Healthcare GmbH's business was transferred to Siemens Healthineers AG. Corporate program statement; exact-release scope is not established.
Only appropriately trained healthcare professionals qualified for direct use of diagnostic ultrasound devices should operate or interpret this product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
Monitor by exact hardware, software, model, algorithm, reconstruction, or configuration version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: The FDA submission is a release-specific device record; exact model, transducer, application, software option, patient, and measurement-package applicability must be confirmed before use.
Map installed model, build, options, population, anatomy, inputs, outputs, and enabled functions to K240704 before acceptance. Later family features are not evidence for this exact submission.
The exact FDA material does not establish a complete interoperability contract. Establish and test supported input, output, identity, routing, archive, and downtime behavior locally.
The exact FDA material does not establish hosting, deployment topology, availability, upgrade path, or service responsibility. Obtain site-specific evidence before procurement.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. The FDA submission is a release-specific device record; exact model, transducer, application, software option, patient, and measurement-package applicability must be confirmed before use.
exact submission · checked 2026-09-04
Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs. No exact-product price was found.
Monitor by exact hardware, software, model, algorithm, reconstruction, or configuration version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: The FDA submission is a release-specific device record; exact model, transducer, application, software option, patient, and measurement-package applicability must be confirmed before use.
exact submission · checked 2026-09-04
Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-20Last searched
33Fields reviewed
12Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public list price for the exact cleared or approved configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Deployment: Not publicly available - checked 2026-09-04 - Exact FDA submission
The exact FDA decision material does not establish the complete deployment topology, hosting responsibility, availability, upgrade path, or service contract.
Integration: Not publicly available - checked 2026-09-04 - Exact FDA submission
The exact FDA decision material does not establish a complete integration contract. Confirm DICOM, worklist, identity, interfaces, exports, routing, audit behavior, archive, and downtime locally.
GE Medical Systems Ultrasound and Primary care Diagnostics
Authorized purpose: The Voluson Expert 18, 20, and 22 are general-purpose ultrasound systems for qualified and trained healthcare professionals. The FDA material describes fetal and obstetric, abdominal, pelvic and infertility, pediatric, small-organ, cephalic, cardiac, musculoskeletal, vascular, transvaginal, and transrectal applications and the labeled operating modes.
Authorized purpose: The Samsung V5, H5, XV5, XH5, V4, H4, XV4, and XH4 diagnostic ultrasound systems are intended for diagnostic ultrasound imaging and fluid analysis of the human body by appropriately trained healthcare professionals across the labeled adult, pediatric, fetal, obstetric, abdominal, gynecologic, cardiac, vascular, cephalic, small-organ, musculoskeletal, urologic, and procedural applications.
Authorized purpose: The RS85 diagnostic ultrasound system and probes obtain ultrasound images and analyze body fluids. The FDA indication lists fetal and obstetric, abdominal, gynecologic, intraoperative, pediatric, small-organ, cephalic, transrectal, transvaginal, musculoskeletal, urology, adult and pediatric cardiac, transesophageal cardiac, and peripheral-vessel applications.
GE Medical Systems Ultrasound and Primary care Diagnostics
Authorized purpose: The Voluson Signature 18 and 20 are general-purpose diagnostic ultrasound systems with specialized OB/GYN use. The FDA material describes fetal and obstetric, abdominal, gynecologic, pediatric, small-organ, cephalic, cardiac, vascular, musculoskeletal, urologic, and other labeled applications with the supported ultrasound modes.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.